Abstract:Introduction: In hemorrhaging trauma patients, the endothelium is activated, resulting in excessive endothelial synthesis of von Willebrand Factor (vWF), which may enhance micro-thrombi formation, resulting in obstruction of the microcirculation and endothelial injury, aggravating bleeding, as well as contributing to organ failure. Under normal conditions, vWF is cleaved by the metalloprotease ADAMTS-13. After trauma, ADAMTS-13 levels are reduced. Objectives: To assess whether recombinant human ADAMTS-13 inhibits endothelial injury and organ failure in a rat trauma-transfusion model. Methods: Blood products were prepared from syngeneic rat blood according to blood bank standards. Polytrauma was induced in rats by crush injury to the intestines and liver and by fracture of the femur. The rats were hemorrhaged until a mean arterial pressure (MAP) of 40 mmHg was reached. Rats were randomized to receive transfusion of RBCs, FFPs, and platelets in a 1:1:1 ratio to achieve a MAP of 70 mmHg, with or without the addition of ADAMTS-13 (50 μg/kg). Blood samples were assessed for biochemistry and rotational thromboelastometry (ROTEM). Syndecan-1 and VE-cadherin levels were measured as a reflection of endothelial integrity. The amount of leakage of dextran-FITC from the vascular system to the parenchyma in lungs was quantified. To assess inflammation, IL-6 and IL-8 levels were determined. Organ damage was assessed by histopathology. Results: All rats were severely shocked, with no significant differences in shock parameters between groups. Rats treated with ADAMTS-13 showed signs of a more effective shock reversal (higher blood pressure, lower lactate levels) compared to controls. Also, ROTEM parameters of clot formation in rats receiving ADAMTS-13 improved compared to controls, which was mainly platelet-dependent. Syndecan-1 levels relative to baseline trended to be lower in ADAMTS-13 treated rats compared to controls (107 vs 149%, p = 0.08). ADAMTS-13 reduced albuminuria (1.7 vs 4.4 g/L, p < 0.01) and organ-specific inflammation (pulmonary IL-6 243 vs 369 pg/mL, p = 0.08; splenic IL-6 253 vs 307, p = 0.03) compared to controls, but did not improve histopathological scores. Conclusions: The use of ADAMTS-13 in a rat trauma-transfusion model improves parameters of shock, platelet-driven coagulation, endothelial damage, and organ inflammation. These results suggest that ADAMTS-13 is important in mediating outcome of trauma. Whether ADAMTS-13 can be used as a therapeutic adjunct to treat bleeding trauma patients remains to be determined.

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic Purpura

[Identification of Two Novel Mutations in ADAMTS13 Gene in a Patient with Hereditary Thrombotic Thrombocytopenic Purpura].

[A Clinical Study of Congenital Thrombotic Thrombocytopenic Purpura].

The Highs and Lows of ADAMTS13 Activity

Laboratory Testing for ADAMTS13 for Thrombotic Thrombocytopenia Purpura and Beyond

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative

Diagnostic Challenges in a Case of Immune-Mediated Thrombotic Thrombocytopenic Purpura With Severe ADAMTS13 Deficiency

[Advances in the treatment of thrombotic thrombocytopenic purpura]

Linear relationship between ADAMTS13 activity and platelet dynamics even before severe thrombocytopenia

Therapy of Hereditary Ttp with Adamts13 Deficiency - A Case Report and Review of the Literature.

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura

Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura

ADAMTS13 Inhibits Oxidative Stress and Ameliorates Progressive Chronic Kidney Disease Following Ischaemia/reperfusion Injury.

Pathological Mechanisms and Novel Testing Methods in Thrombotic Thrombocytopenic Purpura

A "backup plan" for ADAMTS13 deficiency in TTP

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura

VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP

Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model